Chris Degnan - 31 Jan 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2026
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 17:16:53 UTC
Previous filing
09 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Degnan Chris Chief Financial Officer 400 ALEXANDER PARK DRIVE, PRINCETON /s/ Jason D. Smith, Attorney-in-Fact 03 Feb 2026 0001741968

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +32,609 $0.000000 32,609 31 Jan 2026 Ordinary Shares 32,609 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.